Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
bluebird bio, Inc. (BLUE) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Quarterly results
08/08/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Sales Agreement, by and between bluebird bio, Inc. and Jefferies LLC",
"Opinion of Latham & Watkins, LLP"
08/08/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CONFIDENTIAL 4 TO GIVE PATIENTS AND THEIR FAMILIES MORE BLUEBIRD DAYS"
08/08/2023 8-K Quarterly results
Docs: "bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress – Continued strong commercial launch for ZYNTEGLO® and SKYSONA®&#59; 16 patient starts across both programs to date –"
07/12/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Update by bluebird bio, Inc",
"Corporate Update by bluebird bio, Inc"
06/12/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "2023 NASDAQ: BLUE EXHIBIT 99.1"
05/09/2023 8-K Quarterly results
Docs: "bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress – Biologics License Application for lovo-cel for sickle cell disease submitted to FDA –"
03/29/2023 8-K Quarterly results
01/19/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, by and among bluebird bio, Inc., Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC",
"Opinion of Latham & Watkins LLP"
01/09/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Corporate Presentation by bluebird bio, Inc",
"Corporate Presentation by bluebird bio, Inc"
01/06/2023 8-K Acquisition/merger/asset purchase announced
Docs: "ASSET PURCHASE AGREEMENT"
01/03/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
12/29/2022 8-K Quarterly results
12/19/2022 8-K Quarterly results
12/12/2022 8-K Other Events  Interactive Data
11/30/2022 8-K Quarterly results
11/07/2022 8-K Quarterly results
Docs: "EMPLOYMENT AGREEMENT",
"– Commercial launch of ZYNTEGLO® underway&#59; on track for first apheresis in the fourth quarter of 2022 – – Chris Krawtschuk appointed chief financial officer –"
09/23/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/19/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys with this devastating and fatal neurodegenerative disease"
09/12/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/17/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
06/23/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
05/02/2022 8-K Quarterly results
04/05/2022 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "bluebird bio Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US Expected to deliver up to $160 million in cost savings over the next two years and extend the Company’s cash runway through pivotal upcoming milestones in the first half of 2023"
03/31/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/07/2022 8-K Quarterly results
03/04/2022 8-K Quarterly results
02/04/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy